Close Navigation
About ArixStrategy
OverviewInvestment caseNewsResultsDocumentsEventsCalendarAnalystsStock infoContact
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

News & Media

Read our latest news, and find more about us and our portfolio companies.

NewsMedia

1st March 2021

C&EN

The fight against fungi

5th February 2021

Investors Chronicle

Bargain shares for 2021

3rd February 2021

LSX Leaders

LSX London 2021 Biotech - Accelerating Innovation Through Early-Stage Investment

26th January 2021

Pharmaphorum

Biden administration – What can the healthcare industry expect?

21st January 2021

OneNucleus

Around the World in Venture Capital

6th January 2021

Citywire

David Stevenson: This is my portfolio for 2021

11th December 2020

Investors chronicle

Exploit Arix Bioscience’s huge margin of safety

11th December 2020

Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment

10th December 2020

Financial Times

Why Tech trend is worth following beyond 2020

3rd December 2020

Shares Magazine

Arix Bioscience shares rise on collaboration deal with Merck KGaA

3rd December 2020

Proactive

Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn

12th November 2020

Shares Magazine

Latest takeovers focus on two specific groups of stocks

23rd September 2020

In Vivo

Deal-Making During A Pandemic And 2021 Expectations

Arix Bioscience

About Arix

The Team

Portfolio

Partners

Insights

News & Events

Contact

Investor Relations

Results Centre

Financial Calendar

Regulatory News

Document Library

Analysts & Advisors

Shareholder Information

Meta

Privacy Policy

Terms of use

Cookie Policy

Arix Bioscience
linkedintwitter

Arix Bioscience plc, registered in England and Wales with company number 09777975

Registered office: 20 Berkeley Square, London W1J 6EQ, United Kingdom

Website by Ether